Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?

TY - JOUR

T1 - Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee

T2 - Where do we go from here?

AU - Eiwegger, Thomas

AU - Anagnostou, Katherine

AU - Arasi, Stefania

AU - Bégin, Philippe

AU - Ben-Shoshan, Moshe

AU - Beyer, Kirsten

AU - Blumchen, Katharina

AU - Brough, Helen

AU - Caubet, Jean Christoph

AU - Chan, Edmond S.

AU - Chen, Meng

AU - Chinthrajah, Sharon

AU - Davis, Carla M.

AU - Des Roches, Anne

AU - Du Toit, George

AU - Elizur, Arnon

AU - Galli, Stephen J.

AU - Håland, Geir

AU - Hoffmann-Sommergruber, Karin

AU - Kim, Harold

AU - Leung, Donald Y.M.

AU - Long, Andrew

AU - Muraro, Antonella

AU - Nurmatov, Ulugbek B.

AU - Pajno, Giovanni B.

AU - Sampath, Vanitha

AU - Saxena, Jamie

AU - Sindher, Sayantani

AU - Upton, Julia

AU - Worm, Margitta

AU - Nadeau, Kari C.

N1 - Funding Information: Supported by the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Naddisy Foundation, Reinhard Foundation, and Food Allergy Research & Education.Disclosure of potential conflict of interest: T. Eiwegger received funding or has research contracts with DBV Technologies, ALK-Abelló, the Food Allergy and Anaphylaxis Program SickKids, and Innovation Funds Denmark and contributions to investigator-initiated oral immunotherapy (OIT) studies. K. Anagnostou has received research contracts with Aimmune Therapeutics and receives honoraria from the American College of Allergy, Asthma and Immunology (ACAAI) and the Colorado Allergy and Asthma Society (CAAS). P. Bégin received grants from Fonds de Recherche en Santé du Québec; the Canadian Allergy, Asthma and Immunology Foundation; DBV Technologies, Sanofi Genzyme; Merck; and Regeneron and personal fees from Aralez, Novartis, and ALK-Abelló outside the submitted work. M. Ben-Shoshan is a coinvestigator for Aimmune and currently involved in OIT studies. K. Beyer reports outside the submitted work grants and personal fees from Aimmune, Danone, and Infectopharm; personal fees from Bencard, Hycor, Mabylon AG, Mylan, and Nestle; and grants from ALK-Abelló, DBV Technologies, and Hipp. K. Blumchen received personal fees and nonfinancial support from Novartis; personal fees from HAL Allergy, Thermo Fisher, Bencard Allergie, Allergopharma, ALK-Abelló, DBV, Nestle, and Nutricia; grants and personal fees from Aimmune Therapeutics; and a grant from Hipp. H. Brough received serves on the UK Advisory Board for DBV Technologies and has received research support from Thermo Scientific. E. S. Chan has received grants from DBV Technologies; received personal fees from Pfizer, Kaleo, Pediapharm, and Leo Pharma; is co-lead of the Canadian Society of Allergy and Clinical Immunology (CSACI) oral immunotherapy (OIT) guidelines; is a member of the scientific advisory board for Food Allergy Canada; and was an expert panel and coordinating committee member of the National Institutes of Allergy and Infectious Diseases (NIAID)–sponsored Guidelines for Peanut Allergy Prevention. S. Chinthrajah received grant support from CoFAR NIAID, Aimmune, DBV Technologies, Astellas, AnaptysBio, Novartis, Regeneron, Stallergenes-Greer, and Boehringer Ingelheim and is a scientific advisory board member for Alladapt Immunotherapeutics. C. M. Davis is a coinvestigator for and has contracts with Aimmune Therapeutics, DBV Technologies, Regeneron, and Allakos and is on the scientific advisory board for DBV Technologies. A. Des Roches received grants from ALK-Abelló and personal fees from Novartis and ALK-Abelló outside the submitted work. G. Du Toit is a scientific advisory board member for Aimmune, is a coinvestigator on Aimmune-funded peanut immunotherapy trials, is a member for the UK Advisory Board for DBV Technologies; holds equity in DBV technologies; and is a lecturer at allergy symposia supported by Pharma companies, including Mylan and Aimmune. S. J. Galli received funding from National Institutes of Health (NIH) grants NIH/NIAID U19AI104209, NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01 AR067145, NIH/NIAID R01 AI125567, and NIH/NIAID R01 AI32494 and the United States–Israel Binational Foundation (grant 2017182). K. Hoffmann-Sommergruber received grants from the Austrian Science Fund and Horizon 2020 (cost action) and travel reimbursement from the European Academy of Allergy and Clinical Immunology (EAACI). H. Kim served as a speaker and/or advisor for ALK-Abelló, Aralez, Astra Zeneca, CSL Behring, Shire, Novartis, Pediapharm, Stallergenes, Kaleo, Sanofi, Pfizer, and Mylan. D. Y. M. Leung is chairman of the Aimmune Therapeutics DSMC; receives funding from NIH grants NIH/NIAMS R01 AR41256, NIH/NIAID U19 AI117673, NIH/ National Center for Research Resources (NCRR) UL1RR025780, NIH/NIAID UM1AI130780, and NIH/NIAID 1UM2AI130836 and consulted for Sanofi, Regeneron, Demira, and Novartis. A. Muraro received speaker's fees from DBV Technologies, Aimmune, and Nestlè Purina outside the submitted work. S. Sindher received grants from Aimmune, DBV Technologies, Sanofi, and Regeneron. J. Upton is a current or prior investigator for DBV Technologies, Aimmune, and Regeneron and is investigator lead on OIT studies (Food Allergy and Anaphylaxis Program SickKids), is on the advisory board Kaleo, is Food Allergy and Anaphylaxis Chair (CSACI), and is a member of the scientific advisory board for Food Allergy Canada. M. Worm reports grants and personal fees from Aimmune, Mylan, ALK-Abelló, DBV Technologies, Allergopharma, Regeneron, Sanofi, EliLilly, Stallergenes, Bencard, HAL, and Novartis outside the submitted work. K. Nadeau received grant support from the NIAID, Food Allergy Research & Education, End Allergies Together, AllerGenis, and Ukko; personal fees from Regeneron, AstraZeneca, ImmuneWorks, and Cour; research sponsorship from Novartis, Sanofi, Astellas, and Nestle; and research sponsorship for clinical trials from Genentech, Aimmune Therapeutics, DBV Technologies, AnaptysBio, Stallergenes-Greer, Regeneron, and Adare Pharmaceuticals and is a Data and Safety Monitoring Board member at Novartis and the National Heart, Lung, and Blood Institute (NHLBI); cofounded Before Brands, Alladapt Immunotherapeutics, and ForTra; is a grant awardee for the NIAID, NHLBI, National Institute of Environmental Health Sciences (NIEHS), and US Environmental Protection Agency (EPA); and is Director for Food Allergy Research & Education and the World Allergy Organization Center of Excellence. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2020/4

Y1 - 2020/4

KW - efficacy

KW - Food allergy

KW - Institute for Clinical and Economic Review

KW - management

KW - peanut allergy

KW - quality of life

KW - safety

KW - treatment

KW - US Food and Drug Administration Allergenic Products Advisory Committee

KW - Academies and Institutes

KW - Administration, Oral

KW - United States

KW - Humans

KW - Desensitization, Immunologic/methods

KW - Advisory Committees

KW - Policy Making

KW - Government Regulation

KW - Peanut Hypersensitivity/immunology

KW - United States Food and Drug Administration

UR - http://www.scopus.com/inward/record.url?scp=85075869296&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2019.10.021

DO - 10.1016/j.jaci.2019.10.021

M3 - Editorial

C2 - 31678426

AN - SCOPUS:85075869296

SN - 0091-6749

VL - 145

SP - 1153

EP - 1156

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 4

ER -